JJ
Therapeutic Areas
Homology Medicines Pipeline
| Drug | Indication | Phase |
|---|---|---|
| HMI-102 | Phenylketonuria (PKU) in adults | Phase 1/2 |
| HMI-103 | Phenylketonuria (PKU) in pediatric patients | Phase 1 |
| HMI-104 / HMI-105 | Metachromatic Leukodystrophy (MLD) | Preclinical |
| HMI-106 | Hunter Syndrome (MPS II) | Preclinical |
Leadership Team at Homology Medicines
AT
Arthur Tzianabos, Ph.D.
President and Chief Executive Officer
AS
Albert Seymour, Ph.D.
President and Chief Scientific Officer
WB
W. Bradford Smith
Chief Financial and Operating Officer
TP
Timothy P. Coughlin
Board Member (Atlas Venture)